Dongwha Pharm.Co.,Ltd (000020.KS)
KRW 6360.0
(-1.7%)
KRW 6360.0
(-1.7%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 27.43 Billion KRW | 34.61% |
| 2022 | 20.38 Billion KRW | 14.06% |
| 2021 | 17.87 Billion KRW | -37.31% |
| 2020 | 28.5 Billion KRW | 203.2% |
| 2019 | 9.4 Billion KRW | -6.62% |
| 2018 | 10.06 Billion KRW | -78.58% |
| 2017 | 47 Billion KRW | 79.05% |
| 2016 | 26.25 Billion KRW | 368.1% |
| 2015 | 5.6 Billion KRW | 13.6% |
| 2014 | 4.93 Billion KRW | 387.93% |
| 2013 | 1.01 Billion KRW | -22.83% |
| 2012 | 1.31 Billion KRW | -92.58% |
| 2011 | 17.67 Billion KRW | 225.75% |
| 2010 | 5.42 Billion KRW | -19.21% |
| 2009 | 6.71 Billion KRW | -76.45% |
| 2008 | 28.51 Billion KRW | 32.67% |
| 2007 | 21.49 Billion KRW | 166.52% |
| 2006 | 8.06 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 3.52 Billion KRW | 17.9% |
| 2024 Q1 | 2.98 Billion KRW | 103.3% |
| 2023 Q2 | 7.5 Billion KRW | -40.12% |
| 2023 Q1 | 12.53 Billion KRW | 406.5% |
| 2023 Q4 | 1.46 Billion KRW | -75.18% |
| 2023 Q3 | 5.92 Billion KRW | -21.13% |
| 2023 FY | 27.43 Billion KRW | 34.61% |
| 2022 Q1 | 5.23 Billion KRW | -8.29% |
| 2022 Q3 | 5.94 Billion KRW | -1.19% |
| 2022 Q4 | 2.47 Billion KRW | -58.35% |
| 2022 FY | 20.38 Billion KRW | 14.06% |
| 2022 Q2 | 6.01 Billion KRW | 14.88% |
| 2021 Q1 | 5.44 Billion KRW | -29.88% |
| 2021 FY | 17.87 Billion KRW | -37.31% |
| 2021 Q2 | 6.26 Billion KRW | 15.05% |
| 2021 Q3 | 447.14 Million KRW | -92.86% |
| 2021 Q4 | 5.71 Billion KRW | 1177.02% |
| 2020 Q4 | 7.76 Billion KRW | -33.93% |
| 2020 Q3 | 11.75 Billion KRW | 74.91% |
| 2020 Q2 | 6.72 Billion KRW | 197.29% |
| 2020 FY | 28.5 Billion KRW | 203.2% |
| 2020 Q1 | 2.26 Billion KRW | -71.57% |
| 2019 Q4 | 7.95 Billion KRW | 3277.12% |
| 2019 Q2 | -628.98 Million KRW | -134.11% |
| 2019 Q1 | 1.84 Billion KRW | 0.0% |
| 2019 FY | 9.4 Billion KRW | -6.62% |
| 2019 Q3 | 235.45 Million KRW | 137.43% |
| 2018 Q4 | - KRW | -100.0% |
| 2018 FY | 10.06 Billion KRW | -78.58% |
| 2018 Q2 | 749.9 Million KRW | -84.08% |
| 2018 Q1 | 4.71 Billion KRW | -88.11% |
| 2018 Q3 | 1.17 Billion KRW | 57.03% |
| 2017 Q3 | 783.91 Million KRW | -75.41% |
| 2017 FY | 47 Billion KRW | 79.05% |
| 2017 Q4 | 39.6 Billion KRW | 4952.52% |
| 2017 Q1 | 3.42 Billion KRW | -82.0% |
| 2017 Q2 | 3.18 Billion KRW | -7.06% |
| 2016 FY | 26.25 Billion KRW | 368.1% |
| 2016 Q1 | 4.78 Billion KRW | 68.67% |
| 2016 Q2 | 978.21 Million KRW | -79.56% |
| 2016 Q3 | 1.43 Billion KRW | 46.99% |
| 2016 Q4 | 19.05 Billion KRW | 1225.12% |
| 2015 Q1 | 1.85 Billion KRW | 42.71% |
| 2015 Q4 | 2.83 Billion KRW | 452.88% |
| 2015 Q3 | -803.94 Million KRW | -146.84% |
| 2015 Q2 | 1.71 Billion KRW | -7.68% |
| 2015 FY | 5.6 Billion KRW | 13.6% |
| 2014 Q2 | 1.32 Billion KRW | -23.55% |
| 2014 Q1 | 1.73 Billion KRW | 200.48% |
| 2014 FY | 4.93 Billion KRW | 387.93% |
| 2014 Q4 | 1.3 Billion KRW | 128.25% |
| 2014 Q3 | 570.76 Million KRW | -57.0% |
| 2013 Q3 | -2.53 Billion KRW | -314.44% |
| 2013 FY | 1.01 Billion KRW | -22.83% |
| 2013 Q1 | 4.09 Billion KRW | 148.51% |
| 2013 Q2 | 1.18 Billion KRW | -71.09% |
| 2013 Q4 | -1.72 Billion KRW | 31.93% |
| 2012 Q4 | -8.43 Billion KRW | -253.42% |
| 2012 Q1 | 1.85 Billion KRW | -52.79% |
| 2012 Q2 | 2.39 Billion KRW | 29.19% |
| 2012 FY | 1.31 Billion KRW | -92.58% |
| 2012 Q3 | 5.5 Billion KRW | 129.64% |
| 2011 FY | 17.67 Billion KRW | 225.75% |
| 2011 Q2 | 5.85 Billion KRW | -13.21% |
| 2011 Q4 | 3.92 Billion KRW | 239.92% |
| 2011 Q1 | 6.74 Billion KRW | 7.3% |
| 2011 Q3 | 1.15 Billion KRW | -80.26% |
| 2010 Q3 | -1.33 Billion KRW | 8.52% |
| 2010 Q4 | 6.28 Billion KRW | 571.84% |
| 2010 Q1 | 1.93 Billion KRW | 0.0% |
| 2010 FY | 5.42 Billion KRW | -19.21% |
| 2010 Q2 | -1.45 Billion KRW | -175.42% |
| 2009 Q2 | 4.06 Billion KRW | -62.65% |
| 2009 Q1 | 10.88 Billion KRW | 79.84% |
| 2009 FY | 6.71 Billion KRW | -76.45% |
| 2009 Q3 | 1.28 Billion KRW | -68.31% |
| 2008 FY | 28.51 Billion KRW | 32.67% |
| 2008 Q3 | 5.29 Billion KRW | -15.73% |
| 2008 Q4 | 6.05 Billion KRW | 14.21% |
| 2008 Q2 | 6.28 Billion KRW | -24.38% |
| 2008 Q1 | 8.31 Billion KRW | 85.05% |
| 2007 Q4 | 4.49 Billion KRW | -12.37% |
| 2007 FY | 21.49 Billion KRW | 166.52% |
| 2007 Q2 | 3.56 Billion KRW | 0.0% |
| 2007 Q3 | 5.12 Billion KRW | 43.9% |
| 2006 FY | 8.06 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 482.101% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 52.684% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 146.048% |
| HANDOK Inc. | -28.79 Billion KRW | 195.28% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 426.057% |
| Yuhan Corporation | 93.5 Billion KRW | 70.657% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | -146.693% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 210.585% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 81.236% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | -682.028% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 1194.723% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | 1423.023% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 706.393% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | -22.861% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 482.101% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 231.027% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | -665.711% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 123.2% |
| JW Holdings Corporation | 19.02 Billion KRW | -44.213% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 134.764% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 87.089% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 25.855% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 147.864% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | -348.209% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | -1549.392% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | -448.246% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 482.101% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 25.773% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 75.392% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 25.855% |
| Yuhan Corporation | 93.5 Billion KRW | 70.657% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 268.854% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 807.986% |
| Suheung Co., Ltd. | 6.11 Billion KRW | -348.395% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 25.855% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | -45.132% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 43.147% |
| CKD Bio Corp. | -24.19 Billion KRW | 213.416% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | -14.723% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 7.846% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 147.864% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 41.63% |
| Boryung Corporation | 40.2 Billion KRW | 31.75% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 187.579% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 1194.723% |
| JW Lifescience Corporation | 28.14 Billion KRW | 2.507% |